Nanotechnology Now - Press Release: Alltracel Pharmaceuticals Plc ("Alltracel" or the "Company") Directors' Shareholding

Home > Press > Alltracel Pharmaceuticals Plc ("Alltracel" or the "Company") Directors' Shareholding

Abstract:
Alltracel CEO Tony Richardson Increases Shareholding

Alltracel Pharmaceuticals Plc ("Alltracel" or the "Company") Directors' Shareholding

DUBLIN and LONDON | Posted on April 17th, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"),(LSE: AP) (AIM:AP.L),
the Healthcare Innovation Group focused on the Wound Care, Oral Care and
Cardiovascular Health markets was informed today that Tony Richardson,
Chief Executive Officer of the Company, acquired 150,000 ordinary shares of
EUR0.0125 each ("Ordinary Shares") on 17 April 2007. The Ordinary Shares
were bought at GBP0.12 p each and following this acquisition, Mr Richardson
now holds a total of 1,885,306 Ordinary Shares, which represents
approximately 1.36 per cent of the Company's issued share capital.

####

About Alltracel Pharmaceuticals Plc
Alltracel, (AIM: AP.L) (http://www.alltracel.com) the Healthcare Innovation
group is focused on taking proprietary technology from research right
through to commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and
is a public company which listed on London's Alternative Investment Market
in July 2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a
commercial office in London, England; R&D subsidiary in the Czech Republic
and manufacturing facilities in Shenzhen, China. Alltracel also has a wide
network of research, development and manufacturing partners in Europe, Asia
and North America.
Alltracel operates via two main divisions Alltracel Healthcare Group
and Alltracel Healthcare Technologies:
Alltracel Healthcare Technologies is focused on the commercialisation
effort behind proven innovation technologies and services for the global
healthcare market. Alltracel Healthcare Group has a range of stake
holdings, joint ventures and wholly owned business units operating in a
variety of healthcare categories including Wound Care, Oral Care,
Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (http://www.westone.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands
internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM)
(http://www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and
is dedicated to the commercialisation of Nanospider(TM) technology for the
global healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by
Nanopeutics s.r.o.

For more information, please click here

Contacts:
For Further Information Contact:

Dublin: Denise Cronin Alltracel: +353-1-235-2162

London: Deborah Scott Financial Dynamics: +44-(0)207-831-3113
New York: Sean Leous Financial Dynamics: +1-212-850-5626

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: